[1] TRAVIS J.Closing in on melanoma susceptibility gene(s)[J].Science,1992,258(5085):1080.
[2] SERRANO M,HANNON GJ,BEACH D.A new regulary motif in cell-cycle control causing specific inhibition of cyclin D/CDK4[J].Nature,1993,366(6456):704.
[3] 华晶,王雅杰.p16基因与乳腺癌关系的研究进展[J].医学研究杂志,2013,42(10):7.
[4] SEOUNG WC,SOHN JH,KIM DH.Overexpressions of cyclin B1,cdc2,p16 and p53 in human breast cancer:the clinicopathologic correlations and prognostic implications[J].Yonsei Med J,2011,52(3):445.
[5] VALLIAN S,SEDAGHAT M,NASSIRI I,et al.Methylation status of p16 INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer[J].J Cancer Res Clin Oncol,2009,135(8):991.
[6] HERMAN JG,MERLO A,MAO L,et al.Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers[J].Cancer Res,1995,55(20):4525.
[7] 胡锐,田超,蒋文军,等.p16基因甲基化在乳腺癌发展中的作用[J].中国普外基础和临床杂志,2011,18(5):553.
[8] LU Y,ZHANG X,ZHANG J.Inhibition of breast tumor cell growth by ectopic expression of p16/INK4A via combined effects of cell cycle arrest,senescence and apoptotic induction,and angiogenesis inhibition[J].J Cancer,2012,3:333.
[9] LI J,YEN C,LIAW D,et al.PTEN,a putative protein tyrosine-phos phatase gene mutated in human brain,breast,and prostate cancer[J].Science,1997,275(5308):1943.
[10] TATE G,SUZUKI T,MITSUYA T.Mutation of the PTEN gene in a human hepatic angiosarcoma[J].Cancer Genet Cytogenet,2007,178(2):160.
[11] PETROCELLI T,SLINGERLAND JM.PTEN deficiency:a role in mammary carcinogenesis[J].Breast Cancer Res,2001,3(6):356.
[12] HAMADA K,SASAKI T,KONI PA,et al.The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis[J].Genes Dev,2005,19(17):2054.
[13] TAMUTA M,GU J,TRAN H,et al.PTEN gene and intergrin signaling in cancer[J].J Natl Cancer Inst,1999,91(21):1820.
[14] STAMBOLIC V,TSAO MS,MACPHERSON D,et al.High incidence of breast and endometrial neop lasia resembling human Cowden syndrome in PTEN+/-mice[J].Cancer Res,2000,60(13):3605.
[15] 李祥勇,周克元,林观平.抑癌基因PTEN对乳腺癌细胞生长增殖的影响[J].海南医学,2010,21(3):8.
[16] TOKUNAGA E,OKI E,KIMURA Y,et al.Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma[J].Breast Cancer Res Treat,2007,101(3):249.
[17] 孙丽梅,王鲁建,宋敏,等.乳腺癌组织突变型p53和抑癌基因PTEN表达及其临床意义的研究[J].中华肿瘤防治杂志,2008,15(6):430.
[18] 李祥勇,曾今诚,林观平,等.野生型PTEN基因在乳腺癌细胞中对表阿霉素的增敏作用[J].肿瘤防治研究,2011,38(11):1232.
[19] EASTMAN A.Cell cycle checkpoints and their impact on anticancer therapeutic strategies[J].J Cell Biochem,2004,91(2):223.
[20] JIANG H,REINHARDT HC,BARTKOVA J,et al.The combined status of ATM and p53 link tumor development with therapeutic response[J].Genes Dev,2009,23(16):1895.
[21] SWIFT M,REITNAUER PJ,MORRELL D,et al.Breast and other cancers in families with ataxia-telengiectasia[J].N Engl J Med,1987,316:1289.
[22] NATHANSON KL,WOOSTER R,WEBER BL.Breast cancer genetics:what we know and what we need[J].Nat Med,2001,7(5):552.
[23] RENWICK A,THOMPSON D,SEAL S,et al.ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles[J].Nat Genet,2006,38(8):873.
[24] RONDEAU S,VACHER S,DE KONING L,et al.ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels[J].Brit J Cancer,2015,112(6):1059.